Af­ter ini­tial com­mer­cial for­ay, Chi­na's CStone mulls sale — re­port

CStone Phar­ma­ceu­ti­cals, the can­cer drug de­vel­op­er be­hind a PD-L1 drug li­censed by Pfiz­er in Chi­na and EQRx around the world, is re­port­ed­ly con­sid­er­ing a sale …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER